Mavacamten Controlled Hypertrophic Cardiomyopathy for >1 Year

Open-label mavacamten for a median of 62 weeks in patients with symptomatic obstructive hypertrophic cardiomyopathy showed ongoing safety and efficacy.
Medscape Medical News

source https://www.medscape.com/viewarticle/971493?src=rss

Comments

Popular posts from this blog

New AAFP practice guideline sets blood pressure targets for adults with hypertension